206 related articles for article (PubMed ID: 25610001)
1. Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy.
Doherty MK; Morris PG
Int J Womens Health; 2015; 7():47-58. PubMed ID: 25610001
[TBL] [Abstract][Full Text] [Related]
2. Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer.
McBride A; Butler SK
Am J Health Syst Pharm; 2012 May; 69(9):745-55. PubMed ID: 22517020
[TBL] [Abstract][Full Text] [Related]
3. Potential clinical applications of halichondrins in breast cancer and other neoplasms.
Ortega V; Cortés J
Breast Cancer (Dove Med Press); 2012 Feb; 4():9-19. PubMed ID: 24367189
[TBL] [Abstract][Full Text] [Related]
4. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.
Cortes J; O'Shaughnessy J; Loesch D; Blum JL; Vahdat LT; Petrakova K; Chollet P; Manikas A; Diéras V; Delozier T; Vladimirov V; Cardoso F; Koh H; Bougnoux P; Dutcus CE; Seegobin S; Mir D; Meneses N; Wanders J; Twelves C;
Lancet; 2011 Mar; 377(9769):914-23. PubMed ID: 21376385
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of eribulin mesylate: a new therapeutic option in the treatment of metastatic breast cancer.
O'Sullivan Coyne G; Walsh J; Kelly CM
Expert Opin Drug Saf; 2012 Jul; 11(4):643-50. PubMed ID: 22694309
[TBL] [Abstract][Full Text] [Related]
6. Eribulin mesylate for the treatment of late-stage breast cancer.
Gourmelon C; Frenel JS; Campone M
Expert Opin Pharmacother; 2011 Dec; 12(18):2883-90. PubMed ID: 22087618
[TBL] [Abstract][Full Text] [Related]
7. Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer.
Muñoz-Couselo E; Pérez-García J; Cortés J
Onco Targets Ther; 2011; 4():185-92. PubMed ID: 22162924
[TBL] [Abstract][Full Text] [Related]
8. Eribulin: a novel cytotoxic chemotherapy agent.
Preston JN; Trivedi MV
Ann Pharmacother; 2012 Jun; 46(6):802-11. PubMed ID: 22619477
[TBL] [Abstract][Full Text] [Related]
9. A comparison of toxicity and health care resource use between eribulin, capecitabine, gemcitabine, and vinorelbine in patients with metastatic breast cancer treated in a community oncology setting.
Dranitsaris G; Beegle N; Kalberer T; Blau S; Cox D; Faria C
J Oncol Pharm Pract; 2015 Jun; 21(3):170-7. PubMed ID: 24620009
[TBL] [Abstract][Full Text] [Related]
10. Eribulin mesylate.
Jain S; Vahdat LT
Clin Cancer Res; 2011 Nov; 17(21):6615-22. PubMed ID: 21859830
[TBL] [Abstract][Full Text] [Related]
11. Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial.
Aftimos P; Polastro L; Ameye L; Jungels C; Vakili J; Paesmans M; van den Eerenbeemt J; Buttice A; Gombos A; de Valeriola D; Gil T; Piccart-Gebhart M; Awada A
Eur J Cancer; 2016 Jun; 60():117-24. PubMed ID: 27107326
[TBL] [Abstract][Full Text] [Related]
12. Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer.
Twelves C; Cortes J; Vahdat LT; Wanders J; Akerele C; Kaufman PA
Clin Breast Cancer; 2010 Apr; 10(2):160-3. PubMed ID: 20299316
[TBL] [Abstract][Full Text] [Related]
13. Advances in therapy: eribulin improves survival for metastatic breast cancer.
Morris PG
Anticancer Drugs; 2010 Nov; 21(10):885-9. PubMed ID: 20838209
[TBL] [Abstract][Full Text] [Related]
14. Eribulin mesylate for the treatment of breast cancer.
Cigler T; Vahdat LT
Expert Opin Pharmacother; 2010 Jun; 11(9):1587-93. PubMed ID: 20450446
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.
Cortes J; Vahdat L; Blum JL; Twelves C; Campone M; Roché H; Bachelot T; Awada A; Paridaens R; Goncalves A; Shuster DE; Wanders J; Fang F; Gurnani R; Richmond E; Cole PE; Ashworth S; Allison MA
J Clin Oncol; 2010 Sep; 28(25):3922-8. PubMed ID: 20679609
[TBL] [Abstract][Full Text] [Related]
16. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
Pernas S; Martin M; Kaufman PA; Gil-Martin M; Gomez Pardo P; Lopez-Tarruella S; Manso L; Ciruelos E; Perez-Fidalgo JA; Hernando C; Ademuyiwa FO; Weilbaecher K; Mayer I; Pluard TJ; Martinez Garcia M; Vahdat L; Perez-Garcia J; Wach A; Barker D; Fung S; Romagnoli B; Cortes J
Lancet Oncol; 2018 Jun; 19(6):812-824. PubMed ID: 29706375
[TBL] [Abstract][Full Text] [Related]
17. Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer.
Scarpace SL
Clin Ther; 2012 Jul; 34(7):1467-73. PubMed ID: 22739019
[TBL] [Abstract][Full Text] [Related]
18. Review on the clinical use of eribulin mesylate for the treatment of breast cancer.
Aseyev O; Ribeiro JM; Cardoso F
Expert Opin Pharmacother; 2016; 17(4):589-600. PubMed ID: 26809667
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial.
Hayashida T; Jinno H; Mori K; Sato H; Matsui A; Sakurai T; Hattori H; Takayama S; Wada M; Takahashi M; Seki H; Seki T; Nagayama A; Matsumoto A; Kitagawa Y
BMC Cancer; 2018 Jun; 18(1):701. PubMed ID: 29954362
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
Vahdat LT; Pruitt B; Fabian CJ; Rivera RR; Smith DA; Tan-Chiu E; Wright J; Tan AR; Dacosta NA; Chuang E; Smith J; O'Shaughnessy J; Shuster DE; Meneses NL; Chandrawansa K; Fang F; Cole PE; Ashworth S; Blum JL
J Clin Oncol; 2009 Jun; 27(18):2954-61. PubMed ID: 19349550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
